All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Molecular response in AML patients with NPM1 and FLT3 mutations undergoing SCT
This month, in a Letter to the Editor of Bone Marrow Transplantation, Rana Salem and colleagues from the American University of Beirut Medical Center (AUBMC), reported results from their retrospective study which evaluated the dynamics of molecular response to treatment in adult Acute Myeloid Leukemia (AML) patients with concomitant Nucleophosmin-1 (NPM1) and Fms Like Tyrosine Kinase 3 (FLT3) mutations at diagnosis and after allogenic Stem Cell Transplantation (SCT).
Twelve de novo AML patients (median age = 45 years) with concomitant NPM1 and FLT3 mutations, who were treated at the AUBMC between January 2011 to December 2016 were included in this retrospective study. Ten patients received allogenic SCT followed by post-transplant sorafenib (tyrosine kinase inhibitor) maintenance. Bone marrow samples were tested for FLT3 and NPM1 gene expression at diagnosis, after induction, after each consolidation, before and at days 30, 60 and 100 after allogenic SCT.
The key results of the study were:
- After induction, FLT3 was negative in all patients (n = 12) and only two patients (2/12) were negative for NPM1 mutation
- After first consolidation, FLT3 mutation remained negative in 11 patients with molecular relapse occurring in one patient
- After first consolidation, NPM1 mutation was negative in three patients and in seven additional patients after allogenic SCT (before sorafenib [n = 4] and after sorafenib [n = 3])
- No molecular positivity for FLT3 was noted after second consolidation or after allogenic SCT
- NPM1 Minimal Residual Disease (MRD) value was elevated in patients (3/4) with quantitative assessment at diagnosis and after induction
In summation, “FLT3 becomes negative early after induction while NPM1 mutation negatively lags behind and may become negative after sorafenib”.
The authors concluded by suggesting that NPM1 mutation is a potential candidate for MRD evaluation post allogenic SCT. They further proposed that the findings of their study should be validated in a large prospective study.
References